The present invention relates to pharmaceutical agents administered to a subject either in combination or in series for the treatment of a Respiratory Syncytial Virus (RSV) infection, wherein treatment comprises administering a compound effective to inhibit the function of the RSV and an additional compound or combinations of compounds having anti-RSV activity.

The present invention relates to pharmaceutical agents administered to a subject either in combination or in series for the treatment of a Respiratory Syncytial Virus (RSV) infection, wherein treatment comprises administering a compound effective to inhibit the function of the RSV and an additional compound or combinations of compounds having anti-RSV activity.

The present disclosure provides methods for treating or preventing an infectious disease or condition, such as the COVID-19 virus (SARS-CoV-2), by administering a therapeutically effective amount of taxifolin to a subject in need thereof, wherein the taxifolin is administered to the subject in combination with a therapeutically effective amount of one or more additional therapeutic agents.

The present disclosure provides methods for treating or preventing an infectious disease or condition, such as the COVID-19 virus (SARS-CoV-2), by administering a therapeutically effective amount of taxifolin to a subject in need thereof, wherein the taxifolin is administered to the subject in combination with a therapeutically effective amount of one or more additional therapeutic agents.

The invention provides therapeutic compositions containing willow extract, such as willow leaf extract, methods of medical treatment using such compositions, and methods for preparing such compositions.

The invention provides therapeutic compositions containing willow extract, such as willow leaf extract, methods of medical treatment using such compositions, and methods for preparing such compositions.

Disclosed are gene risk profiles that predict outcomes in COVID-19. Single-cell analysis reveals immune responses associated with COVID-19 mortality.

Disclosed are gene risk profiles that predict outcomes in COVID-19. Single-cell analysis reveals immune responses associated with COVID-19 mortality.

The present invention includes a vaccine comprising a SARS-CoV-2 spike protein (S) or portion thereof, and methods of use thereof.

Disclosed herein are antibodies or immunogenic fragments thereof that specifically bind to Epstein-Barr virus (EBV) glycoprotein 350 (gp350) or 220 or one or more epitopes of EBV gp350 and neutralize EBV infection. Also disclosed are immunogenic peptides comprising one or more gp350 epitopes, EBV antibody-small molecule conjugates and pharmaceutical compositions comprising the antibody or an immunogenic fragment thereof, one or more epitopes of EBV gp350, one or more immunogenic peptides, or the EBV antibody-small molecule conjugate. The antibodies, epitopes, immunogenic peptides, conjugates, and pharmaceutical compositions can be used to treat or prevent EBV infections and EBV-associated conditions and diseases.